Shares of Intercept Pharmaceuticals fell more than 10 percent following a decision by the company’s board of directors to cut 25 percent of headcount.

A filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company.

CHICAGO – In an Oct. 5 filing with the U.S. Securities and Exchange Commission, Valeant Pharmaceuticals International, Inc. (VRX) fired back at critics over its decisions to grow its pipeline through acquisitions and increase the cost of some newly acquired drugs.   In the filing, Valeant said it is not as dependent on the price […]